Pimonidazole (Synonyms: NSC 380540, Ro 038799) |
| Catalog No.GC41338 |
Pimonidazole is an anoxic marker used in studying intratumoral hypoxia and cell proliferation.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 70132-50-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Pimonidazole is an anoxic marker used in studying intratumoral hypoxia and cell proliferation. Pimonidazole is a 2-nitroimidazole that is reductively activated specifically in hypoxic cells and forms stable adducts with thiol groups in proteins, peptides, and amino acids. The amount of Pimonidazole that is detected is directly proportional to the level of hypoxia within tumors [1-3].
Pimonidazole (80mg/kg; i.p) can be used to study hypoxia near necrosis of C6 rat brain glioma[4]. Pimonidazole can be used as an investigational hypoxia probe in clinical trials. Patients with primary cervical squamous cell carcinoma received a single infusion of Pimonidazole (0.5g/m²; i.v), followed by tumor biopsies 24 hours later. Immunohistochemical staining confirmed hypoxic cells, aiding tumor hypoxia assessment before radiation therapy[5]. 39 intermediate/high risk prostate cancer patients received a single oral dose of Pimonidazole (0.5g/m2) 24h prior to radical prostatectomy surgery. Pimonidazole-defined hypoxia intensity was positively correlated with advanced pathologic stage, tumor invasion, and cribriform and intraductal carcinoma morphology[6]. Pimonidazole can be used as an exogenous hypoxia marker for matrix-assisted laser desorption/ionization (MALDI) MSI. In hypoxic cells, Pimonidazole is reduced and forms reactive products that bind to thiol groups in proteins, peptides, and amino acids. A reductively activated Pimonidazole metabolite can be imaged by MALDI-MSI in a breast tumor xenograft model[7].
References:
[1]. Varia MA, Calkins-Adams DP, et,al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7. doi: 10.1006/gyno.1998.5163. PMID: 9826471.
[2]. Inci ID, Tekin V, et,al. Radioiodination of Pimonidazole as a Novel Theranostic Hypoxia Probe. Curr Radiopharm. 2021;14(1):46-50. doi: 10.2174/1874471013666200331114908. PMID: 32228432.
[3]. Aguilera KY, Brekken RA. Hypoxia Studies with Pimonidazole in vivo. Bio Protoc. 2014 Oct 5;4(19):e1254. doi: 10.21769/bioprotoc.1254. PMID: 27453908; PMCID: PMC4956402.
[4]. Zoula S, Rijken PF, et,al. Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. Br J Cancer. 2003 May 6;88(9):1439-44. doi: 10.1038/sj.bjc.6600837. PMID: 12778075; PMCID: PMC2741029.
[5]. Kennedy AS, Raleigh JA, et,al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):897-905. doi: 10.1016/s0360-3016(96)00539-1. PMID: 9128967.
[6]. Ci X, Chen S, et,al. Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer. BMC Cancer. 2024 Jun 18;24(1):744. doi: 10.1186/s12885-024-12505-1. PMID: 38890593; PMCID: PMC11186205.
[7]. Mascini NE, Cheng M, et,al. Mass Spectrometry Imaging of the Hypoxia Marker Pimonidazole in a Breast Tumor Model. Anal Chem. 2016 Mar 15;88(6):3107-14. doi: 10.1021/acs.analchem.5b04032. Epub 2016 Feb 29. PMID: 26891127.
Preparation of hypoxic section of C6 rat brain glioma [1]:
1. Experimental model of intracerebral glioma: 5μl of C6 cell suspension, 105 cells, were stereotactically injected 3mm below the dura in the right caudate nucleus of six female Wistar rats (160–180g).
2. Experiments were carried out by the end of the tumour development (22–25 days after tumour cell implantation).
3. Rats were injected with a 0.25ml solution of Pimonidazole in phosphate-buffered saline (PBS, pH 7.4) (80mg/kg of body weight).
4. These markers were administrated intravenously via one of the tail veins, 60 and 1min before killing, respectively. Brains were quickly removed (less than 3min after the rat death), frozen in liquid nitrogen then stored at −80℃.
5. For each rat, transversal section (5μm thick) was cut at mid-tumour (where the tumour was the largest) and analysed on the digital image analysis system.
This experiment is from the literature, please modify according to the specific situation.
References:
[1]. Zoula S, Rijken PF, et,al. Pimonidazole binding in C6 rat brain glioma: relation with lipid droplet detection. Br J Cancer. 2003 May 6;88(9):1439-44. doi: 10.1038/sj.bjc.6600837. PMID: 12778075; PMCID: PMC2741029.
| Cas No. | 70132-50-2 | SDF | |
| Synonyms | NSC 380540, Ro 038799 | ||
| Chemical Name | α-[(2-nitro-1H-imidazol-1-yl)methyl]-1-piperidineethanol | ||
| Canonical SMILES | OC(CN1CCCCC1)CN2C([N+]([O-])=O)=NC=C2 | ||
| Formula | C11H18N4O3 | M.Wt | 254.3 |
| Solubility | 10mg/mL in ethanol,or DMSO of DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9324 mL | 19.6618 mL | 39.3236 mL |
| 5 mM | 786.5 μL | 3.9324 mL | 7.8647 mL |
| 10 mM | 393.2 μL | 1.9662 mL | 3.9324 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *